This is just the beginning! Our collection holds over 300 years of history, including rare newspapers, obituaries, marriage records, birth records, and so much more—most of which you won’t find anywhere else!
Novo Nordisk faces fierce Ozempic race in China market
Novo Nordisk confronts intensifying Chinese competition as at least 15 generic semaglutide versions target Ozempic and Wegovy. China, with the world's largest overweight population, saw Ozempic sales reach 698 million in greater China last year, while Wegovy awaits approval amid patent expiry looming in 2026. Chinese firms CSPC, United Laboratories, Hangzhou Jiuyuan Gene Engineering and others push final trials as unicorns of cost pressure and regulatory risk loom.
MENTIONED IN THIS ARTICLE
Shanghai - Novo Nordisk
China
Novo Nordisk
Greater
Novo
Reuters
Karan Verma
Clarivate
Hangzhou Jiuyuan Gene Engineering
Japan
Europe
U.S
Patent Office
United
United Laboratories
Goldman Sachs
Verma
Maziar
Mike Doustdar
Eli Lilly
HSBC
Lilly
Zuo Ya-Jun
Shanghai Benemae Pharmaceutical
Ozempic
Greater China
Hollie Adams